Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03628612 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 1 entry Study sites: 8 to 9 · Secondary endpoints: details revised at 6 of 7 entries · Eligibility criteria expanded, about 4 words Show 3 more changesShow less
    • Study sites: 8 to 9
    • Secondary endpoints: details revised at 6 of 7 entries
    • Eligibility criteria expanded, about 4 words
  2. Re-verified, no change to tracked fieldsv9
  3. Primary endpoint revised Study sites: 4 to 8 · Start date: Aug 3, 2018 to Aug 2, 2018 · Secondary endpoints: 5 to 7 · 2 morev8 Show 5 more changesShow less
    • Study sites: 4 to 8
    • Start date: Aug 3, 2018 to Aug 2, 2018
    • Secondary endpoints: 5 to 7
    • Study description expanded, about 58 words
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Jul 2032 to Jul 2043 Completion date: Dec 2032 to Dec 2043v7 Show 1 more changeShow less
    • Completion date: Dec 2032 to Dec 2043
  5. Study sites: 6 to 4 Secondary endpoints revised (5)v6 Show 1 more changeShow less
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

Show 4 earlier versionsHide 4 earlier versions
  1. Secondary endpoints: 4 to 5 Study description shortened, about 6 wordsv5 Show 1 more changeShow less
    • Study description shortened, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites revised (6)v4 See this version in full on ClinicalTrials.gov ↗
  3. 2 versions Re-verified since Jan 15, 2019, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Autolus Limited
7 trials monitored
See 1 trial at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
Multiple Myeloma
1,231 trials monitored
See 77 trials at risk
Acute Lymphoblastic Leukemia (ALL)
885 trials monitored
See 51 trials at risk
and 1 more disease
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
Trial Details
NCT Number NCT03628612
Lead Sponsor Autolus Limited
Conditions Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov